trending Market Intelligence /marketintelligence/en/news-insights/trending/R4XlbsRX-B9Cc4YopMyRbA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Allergan files application with US FDA for uterine fibroids treatment

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Allergan files application with US FDA for uterine fibroids treatment

The U.S. Food and Drug Administration accepted Allergan plc's new drug application for ulipristal acetate, an investigational drug to treat abnormal uterine bleeding in women with uterine fibroids.

Allergan expects the drug to be approved in the first half of 2018.

The company previously reported positive results from the second of two phase 3 clinical trials of ulipristal acetate.